Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $990,000.00
Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to announce $990,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Achaogen’s earnings. The highest sales estimate is $1.28 million and the lowest is $800,000.00. Achaogen posted sales of $10.73 million during the same quarter last year, which suggests a negative year over year growth rate of 90.8%. The company is scheduled to issue its next earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Achaogen will report full-year sales of $990,000.00 for the current year, with estimates ranging from $9.30 million to $14.00 million. For the next year, analysts expect that the business will post sales of $13.39 million per share, with estimates ranging from $4.87 million to $25.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $2.09 million. Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The business’s revenue was down 96.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.41) earnings per share.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/14/achaogen-inc-akao-expected-to-post-quarterly-sales-of-990000-00.html.
Achaogen (NASDAQ:AKAO) opened at $12.56 on Tuesday. Achaogen has a 52-week low of $4.67 and a 52-week high of $27.79. The company has a quick ratio of 6.99, a current ratio of 6.99 and a debt-to-equity ratio of 0.08.
In other Achaogen news, COO Blake Wise sold 3,576 shares of Achaogen stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.36% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new stake in shares of Achaogen in the 2nd quarter valued at approximately $168,000. Sigma Planning Corp raised its stake in shares of Achaogen by 9.6% in the 2nd quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 825 shares during the period. Bank of Montreal Can raised its stake in shares of Achaogen by 33.3% in the 2nd quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 2,500 shares during the period. Ardsley Advisory Partners purchased a new stake in shares of Achaogen in the 2nd quarter valued at approximately $217,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Achaogen by 691.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 9,677 shares during the period. 83.81% of the stock is currently owned by institutional investors and hedge funds.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.